15-17 April, 2019

The Waldorf Hilton

London, UK

In this shifting healthcare paradigm and with emerging technology, such as liquid biopsies and NGS panels, generating novel biomarker signatures that are demonstrating their predictive power for patient selection and treatment decisions, now is the time to harness a fully-fledged diagnostic platform to efficiently bring your targeted drug candidates to market.

With impactful European environmental factors, such as Brexit, the impending IVDR and the fierce competition for marketshare, momentum is gaining for the application of patient stratifying diagnostics to close the gap on unmet patient need.

Built for precision medicine, diagnostic and commercial leaders, the World CDx stream will tackle challenges along the development and commercial continuum to ensure the application of a diagnostic strategy ultimately maximises the market penetrate and market share of your precision medicines.

Key Topics to be Addressed in 2019:

symbol logo Establishing “universal” panel diagnostics as the standard of care and exploring their application in biomarker development and treatment decision making
 symbol logo Evaluating the impact of IVDR and how Dx & pharma industries will be impacted by the impending regulatory shift
 symbol logo Navigating the reimbursement landscape of European payers to expand your global adoption of drug-Dx products
symbol logo Enhancing commercialization strategies to expand the global footprint of Dx testing